Overview

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

Status:
Completed

Trial end date:
2018-07-02

Target enrollment:

Participant gender:

Summary

This is a phase 1, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of opicapone when administered orally once daily for 14 days as adjunctive therapy to carbidopa/levodopa in subjects with Parkinson's disease.

Phase:

Phase 1

Details

Lead Sponsor:

Neurocrine Biosciences

Treatments:

Carbidopa
Carbidopa, levodopa drug combination
Levodopa
Opicapone